Sanbo Hospital Management Group (SZSE:301293) Strong Profits May Be Masking Some Underlying Issues
Sanbo Hospital Management Group (SZSE:301293) Strong Profits May Be Masking Some Underlying Issues
The market for Sanbo Hospital Management Group Limited's (SZSE:301293) stock was strong after it released a healthy earnings report last week. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.
上週發佈了良好的業績後,Sanbo醫院管理集團股票市場表現強勁。儘管如此,我們的分析表明,一些因素正在削弱那些良好利潤數字的基礎。
Check out our latest analysis for Sanbo Hospital Management Group
點擊查看我們對Sanbo醫院管理集團的最新分析。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
For anyone who wants to understand Sanbo Hospital Management Group's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥15m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Sanbo Hospital Management Group doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
對於任何想了解Sanbo醫院管理集團利潤的人來說,重要的是要注意,在過去的十二個月中,法定利潤從1500萬元的飛凡項目中獲得。雖然我們喜歡看到利潤增加,但當飛凡項目對利潤貢獻很大時,我們往往會更加謹慎。當我們對上市公司的成千上萬數據進行分析時,我們發現,在某一年中從飛凡項目中獲得的提振通常不會在下一年重複。這並不奇怪,考慮到名稱。如果Sanbo醫院管理集團沒有看到飛凡項目的貢獻得到重複,那麼其他所有條件相等,我們預計它的利潤將在當前年度下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sanbo Hospital Management Group.
注意:我們始終建議投資者檢查資產負債表的實力。單擊此處,以獲取我們對Sanbo醫院管理集團資產負債表分析的詳細信息。
Our Take On Sanbo Hospital Management Group's Profit Performance
我們對Sanbo醫院管理集團利潤表現的看法。
Arguably, Sanbo Hospital Management Group's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Sanbo Hospital Management Group's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 15% per annum growth in EPS for the last three. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 1 warning sign for Sanbo Hospital Management Group and we think they deserve your attention.
可以說,Sanbo醫院管理集團的法定收益已被提振的飛凡項目所扭曲。因此,我們認爲Sanbo醫院管理集團的法定利潤可能比其潛在盈利能力更好。但至少持有者可以從過去三年每年15%的EPS增長中獲得一些安慰。本文的目的是評估我們如何依賴法定收益反映公司潛力,但還有許多問題需要考慮。鑑於此,如果您想對公司進行更多分析,了解所涉風險是至關重要的。在Simply Wall St方面,我們發現Sanbo醫院管理集團存在1個風險警告,我們認爲它們值得您的關注。
Today we've zoomed in on a single data point to better understand the nature of Sanbo Hospital Management Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
今天,我們關注了一個單一的數據點,以更好地了解Sanbo醫院管理集團的利潤性質。但是,如果您能夠集中注意力關注細節,總會有更多發現。有些人認爲高資產回報率是高質量企業的好跡象。雖然您可能需要進行一些研究,但您可能會發現這個免費的高回報率公司集合或這個內部人員正在購買的股票清單很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。